Almonty's Q3 Profit Is Mostly Paper: What the Sangdong Ramp-Up Actually Earned
Published on 11/16/2026 at 17:50 | Editorial boerse-global.deAlmonty's third-quarter headline number looks like a breakout. It isn't — or at least, not in the way the raw figure suggests. The tungsten miner reported a net profit of C$50.2 million for Q3 2026, up 51% year on year, but C$47.9 million of that came from non-cash net gains tied to the revaluation of derivatives and warrant instruments. Strip those out and the picture changes sharply, which is why the more instructive lens on the quarter is the C$14.6 million in adjusted EBITDA and the C$41.9 million in revenue — a 382% surge over the prior year.
That revenue jump reflects genuine expansion of the business, not a balance-sheet adjustment. The distinction matters: sales growth and earnings quality are separate tests, and conflating the two risks crediting the operating business with income that originated somewhere else entirely. The relevant question isn't whether the reported profit is "real" or "fake" — it's whether it stems from ongoing operations or from valuation effects.
Offtake Locked In, Costs Still the Wild Card
Underpinning the growth story is Sangdong, where more than 90% of the first production phase is committed long-term to Global Tungsten & Powders. Almonty is targeting annual ore processing of up to 1.2 million tonnes in 2027. Separate offtake agreements in Rwanda cover more than 100 tonnes of tungsten ore per month, complementing the expansion outlook though distinct from the planned Sangdong throughput.
Those contracts give a large slice of the first phase a guaranteed buyer — but they answer a different question than profitability does. Volume committed on paper still has to be produced at economically viable cost. A planned capacity is not the same as ore actually processed, and sales certainty and earning power deserve to be judged apart.
Should investors sell immediately? Or is it worth buying Almonty?
Cost pressure is precisely where Stifel focused. The brokerage trimmed its price target on Almonty to US$18 from US$21 on Friday, according to media reports, while keeping its buy recommendation intact. The unchanged positive rating sitting beside a more cautious valuation tells its own story: higher costs don't erase the growth case in Stifel's view, but they do reduce what that growth is judged to be worth.
A Legal Fight That Stands on Its Own
Meanwhile, Deutsche Rohstoff disclosed on Wednesday that it is suing Almonty in Canada for roughly US$67 million, a claim that includes 3.5 million conversion shares as well as repayment of debt. According to Deutsche Rohstoff, Almonty has filed a related countersuit.
That dispute doesn't disappear because Almonty's balance sheet looks strong. The company reported cash of C$1.15 billion as of September 30 — a stock measure, not an earnings one, and no substitute for a valuation of the equity. A hefty cash position doesn't neutralize a claim, and a lawsuit is not yet a fixed payment obligation either.
Almonty at a turning point? This analysis reveals what investors need to know now.
For investors, the takeaway is a three-part framework rather than a single verdict. The revenue growth warrants attention, the net profit demands careful decomposition, and the litigation calls for its own separate risk assessment. None of those layers should be allowed to obscure the others — least of all a headline profit that, on close inspection, was largely accounting.
Ad
Almonty Stock: New Analysis - 16 November
Fresh Almonty information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
